NewAmsterdam Pharma Company N.V. has grown revenue −40% a year over three years and −40% a year over five. Revenue growth, 3-year annual rate: −40% (Biotechnology median +21%). Revenue growth, 5-year rate: −40%, growth has slowed since the five-year average. Years of annual history on file: 5, FY2021 to FY2025, as filed.

NAMSNewAmsterdam Pharma Company N.V.

HealthcareUSD

$27.41

$23.9552 weeks$41.45

Is it growing?

Is NAMS growing?

NewAmsterdam Pharma Company N.V. has grown revenue −40% a year over three years and −40% a year over five.

−40%

Revenue growth, 3-year annual rate · Biotechnology median +21% · shrinking · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: −40%
Revenue growth, 5-year rate · −40% over three · growth has slowed since the five-year average
Years of annual history on file: 5
Years of annual history on file · FY2021 to FY2025, as filed

Details›